Clinical trials: terminated
Colitis Ulcerative, Crohn's Disease
A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)
LTS19689 is a multinational, multicenter extension study to evaluate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn's disease (CD) or ulcerative colitis (UC) who completed the 52-week…
- Trial name
- NCT07222189
- Testing
- balinatunfib
- Where
- 10 sites in United States, Argentina and 5 more
- Volunteers
- 7 people
- Sponsor
- Sanofi
Graft Versus Host Disease, Acute
A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD
This study is a prospective randomized placebo-controlled phase 2 study to compare CYP-001 plus corticosteroids (CS) to placebo plus CS in allogeneic hematologic stem cell transplant recipients with HR-aGvHD.
- Trial name
- NCT05643638
- Testing
- CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Corticosteroids
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 65 people
- Sponsor
- Cynata Therapeutics Limited
Hepatocellular Carcinoma (HCC)
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- NCT06487559
- Testing
- Livmoniplimab, Budigalimab
- Where
- 11 sites in China
- Volunteers
- 3 people
- Sponsor
- AbbVie
ALS
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point…
- Trial name
- NCT05151471
- Testing
- MT-1186
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 202 people
- Sponsor
- Shionogi
Advanced or Metastatic Solid Tumors
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults…
- Trial name
- NCT05382325
- Testing
- MK-1484, Pembrolizumab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Atrial Fibrillation
Peripheral Nerve Stimulation Therapy for Atrial Fibrillation
This is a three-arm, single-blinded, randomized, sham-controlled, nonsignificant risk study to assess the feasibility of reducing Atrial Fibrillation burden with peripheral nerve stimulation.
- Trial name
- NCT05653583
- Testing
- Wrist Device, Ear Device
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cala Health, Inc.
Colitis Ulcerative
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC.
- Trial name
- SPECIFI-UC (NCT06867094)
- Testing
- SAR441566
- Where
- 117 sites in United States, Argentina and 22 more
- Volunteers
- 170 people
- Sponsor
- Sanofi
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This was Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- KontRASt-03 (NCT05358249)
- Testing
- JDQ443, trametinib, Ribociclib
- Where
- 13 sites in United States, Belgium and 6 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Emergency Department Triage
PREMEDICAL is a Clinical Investigation Aiming to Create a Data Basis That Can be Used to Enrich Information Collected in the Course of the Classic Patient Journey. Patients in the Emergency Department Will be Asked to Answer Patient-related and Symptom-oriented Questions. Minimum Age is 18 Years
The goal of this clinical investigation is to create a new type of data basis that can be used to enrich information collected in the course of the classic patient journey, such as medical history forms and discharge letters.
- Trial name
- NCT06933550
- Where
- Austria
- Volunteers
- 351 people
- Sponsor
- XUND Solutions GmbH
Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
- Trial name
- NCT06603246
- Testing
- GDC-6988
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Genentech, Inc.
Parkinson Disease
Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally…
- Trial name
- SmIle (NCT06003608)
- Testing
- Fluid biopsy capsule, Levodopa-Carbidopa Immediate Release
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Oral Surgical Procedures
Retrospective Observational Study of Implant-supported Restorations With Dental Implants.
This retrospective study aims to value the bone loss and the success and survival of the dental implants produced by additive manufacturing installed in an area grafted with Plenum® Osshp (synthetic bone graft).
- Trial name
- NCT06154057
- Testing
- Dental Implants installed in an grafted area (sinus lifting), Dental Implants installed in an grafted area (ridge augmentation), Dental Implants installed in an grafted area (extraction sites)
- Where
- Brazil
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- M3 Health
Advanced Solid Tumor
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
- Trial name
- NCT05879822
- Testing
- INCB099280
- Where
- 54 sites in Brazil, China and 7 more
- Volunteers
- 73 people
- Sponsor
- Incyte Corporation
Cutaneous Squamous Cell Carcinoma
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma.
- Trial name
- NCT05888844
- Testing
- INCB099280
- Where
- 77 sites in Australia, Brazil and 13 more
- Volunteers
- 63 people
- Sponsor
- Incyte Corporation
Hypertension, Resistant to Conventional Therapy
Baroloop Multicenter Trial (Baroloop MCT)
The goal of this clinical trial is to learn weather the baroloop system is safe and works to treat hypertension in adults that do not respond sufficiently to medication.
- Trial name
- NCT06518915
- Testing
- baroloop system
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 3 people
- Sponsor
- neuroloop GmbH
Ovarian Cancer
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects…
- Trial name
- NCT05601752
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 21 people
- Sponsor
- USWM CT, LLC
Ovarian Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory…
- Trial name
- NCT04729387
- Testing
- Alpelisib, Olaparib, Paclitaxel
- Where
- 93 sites in United States, Argentina and 24 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Gene Mutations, Pseudoxanthoma Elasticum
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
The purpose of this study (Study INZ701-304 [ADAPT]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to…
- Conditions
- Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
- Trial name
- NCT06462547
- Testing
- INZ-701
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Inozyme Pharma
Colorectal Cancer Metastatic
EO4010 in Previously Treated Metastatic Colorectal Carcinoma
Open-label multicenter study
- Trial name
- AUDREY (NCT05589597)
- Testing
- EO4010
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 25 people
- Sponsor
- Enterome
Acute Myeloid Leukemia
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
This was a parallel, Phase 1/Phase 2, randomized, open label, multi-cohort, multi-center study assessing the safety, tolerability and preliminary efficacy of SAR443579 with different agents for treatment in adolescent and/or…
- Trial name
- NCT06508489
- Testing
- SAR443579, venetoclax, azacitidine
- Where
- 7 sites in United States, Australia
- Volunteers
- 7 people
- Sponsor
- Sanofi